Label Update
A revision to a drug's approved prescribing information or SmPC, typically to add new safety warnings, updated adverse event data, new indications, or modified dosing recommendations. Label updates may be required by regulatory authorities based on post-marketing safety findings.
Technical Context
Label updates (labelling supplements in the US, type II variations in the EU) modify the approved prescribing information based on new safety or efficacy data. Common triggers: new safety signals from post-marketing surveillance (adding warnings, contraindications, or adverse reactions), new clinical trial data (updating efficacy sections), new drug interactions identified, changes to dosing recommendations, and new indication approvals. The process requires regulatory submission with supporting data — the FDA reviews labelling supplements under PDUFA timelines, while the EMA CHMP assesses type II variations. Safety-related label updates may be expedited. For peptide drugs, label updates have included: addition of cardiovascular benefit data to GLP-1 RA labels, revised thyroid monitoring recommendations, and updated injection technique guidance.